Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries

• Published in: Vox sanguinis Vol. 116; no. 1; pp. 18 - 35
• Main Authors: Bloch, Evan M., Goel, Ruchika, Wendel, Silvano, Burnouf, Thierry, Al‐Riyami, Arwa Z., Ang, Ai Leen, DeAngelis, Vincenzo, Dumont, Larry J., Land, Kevin, Lee, Cheuk‐kwong, Oreh, Adaeze, Patidar, Gopal, Spitalnik, Steven L., Vermeulen, Marion, Hindawi, Salwa, Van den Berg, Karin, Tiberghien, Pierre, Vrielink, Hans, Young, Pampee, Devine, Dana, So – Osman, Cynthia
• Format: Journal Article
• Language: English
• Published: England S. Karger AG 01.01.2021; John Wiley and Sons Inc
• Subjects: Antibodies; Blood Donors; blood transfusion; Clinical trials; COVID-19; COVID-19 - therapy; COVID-19 Serotherapy; Developing Countries; Guidelines as Topic; Health Care Surveys; Humans; Immunization, Passive; Income; Infectious diseases; Original Paper; Original Papers; Procurement; SARS-CoV-2; Standardization; Subgroups; Transfusion; COVID-19; blood donors; blood transfusion; COVID-19 serotherapy; SARS-CoV-2

Background and objectives COVID‐19 convalescent plasma (CCP) has been used, predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low‐ and middle‐income cou...